Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy (2015)

We recently reported that BRAF V600E is the principal oncogenic driver of papillary craniopharyngioma, a highly morbid intracranial tumor commonly refractory to treatment. Here, we describe our treatment of a man age 39 years with multiply recurrent BRAF V600E craniopharyngioma using dabrafenib (150mg, orally twice daily) and trametinib (2mg, orally twice daily). After 35 days Read more about Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy (2015)[…]

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets (2015)

Brain metastases are associated with a dismal prognosis. Whether brain metastases harbor distinct genetic alterations beyond those observed in primary tumors is unknown. We performed whole-exome sequencing of 86 matched brain metastases, primary tumors, and normal tissue. In all clonally related cancer samples, we observed branched evolution, where all metastatic and primary sites shared a Read more about Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets (2015)[…]